Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug DM005 enters first human tests for advanced cancers

NCT ID NCT06515990

Recruiting now Disease control Sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the disease. Participants receive DM005 by IV infusion every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DM005 (an experimental drug given by IV infusion)
What this could lead to
If this trial shows DM005 is safe and effective, it could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human Phase 1 trial with only 136 participants. The drug may not work or could cause serious side effects like neurological toxicities. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma colorectal cancer gastroesophageal cancer head and neck squamous cell carcinoma hepatocellular carcinoma malignant pancreatic neoplasm non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG SOLID CARCINOMA SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chris O'Brien Lifehouse

    RECRUITING

    Camperdown, New South Wales, Australia

    Contact

  • Henry Ford Cancer Institute

    RECRUITING

    Detroit, Michigan, 48202, United States

    Contact

  • ICON Cancer Center

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

    Contact

  • Macquarie University Hospital

    RECRUITING

    North Ryde, New South Wales, Australia

    Contact

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

  • Sarah Cannon Research Institute at Mary Crowley

    RECRUITING

    Dallas, Texas, 75251, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.